Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Lung Cancer Clinical Trials

130 recruiting trials for Lung Cancer. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
130
Total Trials
130
Recruiting Now
8
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGNCT06183762

A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer

This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical...

Sponsor: Hunan Province Tumor HospitalEnrolling: 2001 location
RECRUITINGPhase 2NCT05468242

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus...

The phase II Study is to explore the efficacy and safety of Tislelizumab as consolidation therapy in patients with locally advanced non-small cell lung cancer who have not...

Sponsor: Sun Yat-sen UniversityEnrolling: 1161 location
RECRUITINGNCT07359586

Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia

This study retrospectively analyzed patients who underwent tracheal intubation under general anesthesia at the First Affiliated Hospital of Zhejiang University School of Medicine...

Sponsor: Zhejiang UniversityEnrolling: 12002 locations
RECRUITINGNCT06360822

Increasing Equity in Lung Cancer Screening

The overall objective of this mixed methods study is to: 1) Refine the Emergency Department Lung Cancer Screening (ED-LCS) intervention using qualitative interviews among key...

Sponsor: Indiana UniversityEnrolling: 1441 location
RECRUITINGPhase 2NCT07410975

Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage...

This study aims to evaluate the major pathologic response (MPR) rate of neoadjuvant therapy with sintilimab (PD-1 inhibitor) + IBI310 (anti-CTLA-4 antibody) + chemotherapy, and to...

Sponsor: Shanghai Pulmonary Hospital, Shanghai, ChinaEnrolling: 541 location
RECRUITINGNCT06007261

Validation of Rapid On-site Diagnostics in Early Stage Lung Cancer Sampling With a Higher Harmonic Generation Microscope

The aim of this study is to verify a new microscopic technique in diagnosing patients suspected of lung cancer. Patients will undergo navigational bronchoscopy or surgical...

Sponsor: Radboud University Medical CenterEnrolling: 2501 location
RECRUITINGPhase 2 / Phase 3NCT07063745

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab...

The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy...

Sponsor: Bristol-Myers SquibbEnrolling: 59020 locations
RECRUITINGPhase 1 / Phase 2NCT06051695

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid...

The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC),...

Sponsor: A2 Biotherapeutics Inc.Enrolling: 47412 locations
RECRUITINGPhase 3NCT06043973

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

To evaluate the efficacy and safety of almonertinib plus anlotinib as first-line treatment for advanced non-small cell lung cancer with EGFR sensitive mutation and TP53 mutation....

Sponsor: Qianfoshan HospitalEnrolling: 981 location
RECRUITINGNCT05638269

A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China

The human gut microbiome has been associated with many health factors but variability between studies limits the exploration of effects between them. This study aims to...

Sponsor: Zhujiang HospitalEnrolling: 1200020 locations
RECRUITINGNCT06628102

Improving Detection of Early Lung Cancer in a Diverse Population (IDEAL) Study

The goal of this trial is to (a) identify people at high risk of lung cancer who would benefit from LDCT screening but are currently ineligible based on current lung cancer...

Sponsor: British Columbia Cancer AgencyEnrolling: 36001 location
RECRUITINGNCT06496360

Prediction of Mediastinal Station IV Lymph Node Metastasis in Non-small Cell Lung Cancer

Mediastinal lymph node metastasis is a common metastasis pathway of non-small cell lung cancer (NSCLC), and its occurrence is closely related to the lymphatic drainage pattern,...

Sponsor: Qilu Hospital of Shandong UniversityEnrolling: 1501 location
RECRUITINGNCT05754203

Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC

Investigators intend to combine low-dose hypersensitivity with high-dose immunopotentiation effect, and use super-hyperfractionation pulse radiotherapy, which is expected to...

Sponsor: Xinqiao Hospital of ChongqingEnrolling: 402 locations
RECRUITINGPhase 2NCT06249854

Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced...

This is a multicenter, open-label, randomized controlled clinical trial designed to evaluate the efficacy and safety of combination therapy with Bojungikki-tang(BJIKT) and...

Sponsor: Korea Institute of Oriental MedicineEnrolling: 707 locations
RECRUITINGNCT03706027

Study Comparing Two Different Schedules of Radiation for Early-stage Lung Cancer

This study's goal is to find out if the kind of side effects people experience from radiation is different depending on the schedule of their radiation treatment. Patients will be...

Sponsor: University of RochesterEnrolling: 1001 location
RECRUITINGPhase 2NCT06667154

Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy

The primary objective of this study is to assess the major pathological response (MPR) rate and pathologic complete response (pCR) rate in stage IB-IIIA non-small cell lung cancer...

Sponsor: Aline Fusco Fares, MDEnrolling: 331 location
RECRUITINGNCT06638554

Integrating Telehealth to Advance Lung Cancer Screening

The goal of this pragmatic trial is to learn if telehealth strategies can increase shared decision-making (SDM) for lung cancer screening (LCS). It will also learn about the...

Sponsor: Abramson Cancer Center at Penn MedicineEnrolling: 60001 location
RECRUITINGPhase 2NCT03808337

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for...

This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length...

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 14512 locations
RECRUITINGNCT04981119

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect...

Sponsor: A2 Biotherapeutics Inc.Enrolling: 20016 locations
RECRUITINGPhase 2NCT05733000

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With...

This phase II trial tests how well CPI-613 (devimistat) in combination with hydroxychloroquine (HCQ) and 5-fluorouracil (5-FU) or gemcitabine works in patients with solid tumors...

Sponsor: Northwestern UniversityEnrolling: 941 location
RECRUITINGPhase 2NCT06562920

Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung...

To explore the effectiveness and safety of adebrelimab combined with chemotherapy and concurrent SBRT for 3 cycles of neoadjuvant treatment followed by surgery in T1-3N0-1M0...

Sponsor: Zhejiang Cancer HospitalEnrolling: 201 location
RECRUITINGNCT06160596

Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis

This is a retrospective, exploratory, multi-center, translational, 3 cohorts case control matched study conducted in patients harboring a solid tumor with poor prognosis who...

Sponsor: Cure 51Enrolling: 10201 location
RECRUITINGPhase 3NCT07222566

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants...

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with...

Sponsor: PfizerEnrolling: 141017 locations
RECRUITINGNCT05475366

Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures

The aim of this study is to assess the clinical value of 5 transcriptomic signatures prognostic of chemotherapeutic sensitivity to improve the Objective Response Rate (ORR) of...

Sponsor: Institut CurieEnrolling: 857 locations
RECRUITINGPhase 1 / Phase 2NCT06306456

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

This study, including phase Ib , phase IIa and phase IIb, aims to evaluate the safety, tolerability, PK profile, efficacy and to determine the RP2D of GH21 capsules combined with...

Sponsor: Suzhou Genhouse Bio Co., Ltd.Enrolling: 946 locations
RECRUITINGNCT03199651

Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer

This randomized clinical trial studies the Beating Lung Cancer in Ohio protocol in improving survival in patients with stage IV non-small cell lung cancer. The Beating Lung Cancer...

Sponsor: Ohio State University Comprehensive Cancer CenterEnrolling: 35841 location
RECRUITINGNCT05985330

Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1...

Based on the use of the patient's natural defences, immunotherapy mobilizes the immune system to recognize and destroy cancer cells, and it has revolutionized the treatment of...

Sponsor: Centre Hospitalier Universitaire DijonEnrolling: 561 location
RECRUITINGPhase 2NCT06127303

Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC

Immunotherapy with programmed death-1(PD-1) inhibitors is now standard therapy for first-line use in patients with driver-negative advanced NSCLC, whether as single-agent or in...

Sponsor: Shanghai Chest HospitalEnrolling: 543 locations
RECRUITINGPhase 3NCT07008716

Omitting CTV for Primary Tumor in LS-SCLC

This randomized controlled non-inferior trial prospectively enrolled patients with limited-stage small cell lung cancer (LS-SCLC). Patients in the experimental group would receive...

Sponsor: Sun Yat-sen UniversityEnrolling: 8522 locations
RECRUITINGPhase 2NCT05800587

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in...

Sponsor: Fox Chase Cancer CenterEnrolling: 2801 location
RECRUITINGNCT06052098

Transbronchial vs Transthoracic Ablation for Early-stage Peripheral Lung Cancer

The purpose of this study is to investigate the efficacy and safety of RFA through a transthoracic or transbronchial approach in the treatment of early-stage peripheral lung...

Sponsor: Hangzhou Broncus Medical Co., Ltd.Enrolling: 1101 location
RECRUITINGNCT03881098

The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy

This protocol pertains specifically to the prospective lung squamous cell carcinoma pre-malignant lesion (PML) cohort that will form a primary study group for the Lung Pre-Cancer...

Sponsor: University of Colorado, DenverEnrolling: 2402 locations
RECRUITINGPhase 1 / Phase 2NCT06303505

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma...

The purpose of this multicentric, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the...

Sponsor: Tubulis GmbHEnrolling: 25015 locations
RECRUITINGNCT07291921

To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics,...

This project aims to innovatively integrate multi-omics data, including plasma metabolomics, radiomics, and cfDNA multi-level information, combined with survival data (e.g., RFS),...

Sponsor: Peking University People's HospitalEnrolling: 1001 location
RECRUITINGPhase 2NCT06229340

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

There is a huge variety of nucleotide substitutions that activate RAS. The search for new "universal" drugs for the RAS pathway that either interfere with RAS upregulation...

Sponsor: N.N. Petrov National Medical Research Center of OncologyEnrolling: 201 location
RECRUITINGPhase 1NCT05544240

Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors

SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that...

Sponsor: Williams Cancer FoundationEnrolling: 201 location
RECRUITINGPhase 3NCT06350097

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced...

The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas...

Sponsor: AstraZenecaEnrolling: 58220 locations
RECRUITINGEarly Phase 1NCT07235280

Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma

This early phase I trial tests the safety and side effects of dapagliflozin given prior to surgery in patients with stage IA lung adenocarcinoma. Dapagliflozin is approved by the...

Sponsor: Jonsson Comprehensive Cancer CenterEnrolling: 481 location
RECRUITINGNCT04631770

Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC

Lung cancer is the leading cause of cancer related death worldwide. Lobectomy or sub-lobectomy with mediastinal lymph node dissection is the standard surgery. About 50% lung...

Sponsor: Tianjin Medical University Cancer Institute and HospitalEnrolling: 13621 location
RECRUITINGNCT06577883

Next Generation Chest X-Ray Tomosynthesis for Screening of Lung Cancer

The goal of this observational clinical trial is to learn if chest tomosynthesis is a potential alternative to computed tomography for the detection of lung cancer. It will also...

Sponsor: University of California, San DiegoEnrolling: 10001 location
RECRUITINGPhase 1 / Phase 2NCT04938817

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for...

This study is a rolling arm study of investigational agents as monotherapy or in combination with pembrolizumab in participants with anti-programmed cell death 1 (PD-1)/...

Sponsor: Merck Sharp & Dohme LLCEnrolling: 11020 locations
RECRUITINGPhase 2NCT06300424

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

Phase II, single-arm, open-label study that assess clinical feasibility and safety of neoadjuvant almonertinib followed by 3 cycles neoadjuvant adebrelimab plus chemotherapy in...

Sponsor: Guangdong Provincial People's HospitalEnrolling: 321 location
RECRUITINGPhase 1NCT06026410

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in...

Sponsor: Kura Oncology, Inc.Enrolling: 30020 locations
RECRUITINGPhase 1NCT04119024

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic...

This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of...

Sponsor: Anusha KalbasiEnrolling: 183 locations
RECRUITINGNCT06491862

RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based...

The study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with a/m non-squamous...

Sponsor: AstraZenecaEnrolling: 25011 locations
RECRUITINGPhase 2NCT05379803

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

EGFR mutated NSCLC patiens with CNS metastases have poor prognosis. High-dose furmonertinib (160mg/day) have produced high CNS PFS and ORR in second-line for EGFR T790M mutated...

Sponsor: Hunan Province Tumor HospitalEnrolling: 401 location
RECRUITINGPhase 1 / Phase 2NCT04956640

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients...

Sponsor: Eli Lilly and CompanyEnrolling: 54020 locations
RECRUITINGPhase 1NCT05979818

Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced...

This study is a prospective single-center Phase I clinical study in patients with EGFR/ALK/ROS1 driver oncogene negative, and advanced or metastatic NSCLC. This study is to...

Sponsor: Second Xiangya Hospital of Central South UniversityEnrolling: 61 location
RECRUITINGPhase 2NCT06246110

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.

Sponsor: Eikon TherapeuticsEnrolling: 7020 locations
RECRUITINGNCT02432560

Safety and Durability of Sirolimus for Treatment of LAM

The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR...

Sponsor: University of CincinnatiEnrolling: 60020 locations

Showing 50 of 130 trials.Search all Lung Cancer trials